SPI 017

Drug Profile

SPI 017

Alternative Names: SPI-017; SPL-017

Latest Information Update: 21 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sucampo Pharmaceuticals
  • Class Antidementias; Fatty acids; Neuroprotectants; Vascular disorder therapies
  • Mechanism of Action Chloride channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Pain; Peripheral arterial disorders

Most Recent Events

  • 13 Feb 2018 Sucampo Pharmaceuticals has been acquired by Mallinckrodt
  • 18 Mar 2013 Discontinued - Phase-I for Peripheral arterial disorders in Japan (IV)
  • 18 Mar 2013 Phase-II clinical trials in Pain associated with lumbar spinal stenosis in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top